Literature DB >> 27651118

Mortality of neonatal respiratory failure from Chinese northwest NICU network.

L Zhang6, Y Qiu4, B Yi5, L Ni3, L Zhang6, Pulati Taxi7, H Li8, Q Zhang9, W Wang10, Z Liu11, L Li12, L Zhao13, H Wang14, B Sun1,2.   

Abstract

OBJECTIVES: We aimed to evaluate the efficacy of respiratory support and surfactant in incidence, management and outcome of neonatal hypoxemic respiratory failure (NRF) in Chinese emerging regional neonatal-perinatal care system in the era of universal health insurance policy. STUDY
DESIGN: Clinical data of NRF were prospectively collected in 12 consecutive months from 2011 to 2012 in 12 neonatal intensive care units (NICU) in major cities of Northwest China. NRF was defined as hypoxemia requiring nasal continuous positive airway pressure (nCPAP) or intratracheal ventilation combined with surfactant for at least 24 h, with associated risk factors, mortality rate and major co-morbidities analyzed.
RESULTS: Among 9816 admissions, there were 1324 NRF cases with 60.2% being preterm. The incidence of NRF was 13.4% with a mortality of 15.5%. The major underlying diseases were respiratory distress syndrome (RDS, 38.9%) and pneumonia/sepsis (38.0%). Only 15.9% of NRF and 33.8% of RDS received surfactant, which contributed to >70% and >85% survival in RDS patients of birth weight (BW) < 1500 g and >1500 g, respectively. Multivariate logistic regression analysis showed that premature rupture of membrane ≥ 24 h, very low BW and gestational age < 32 weeks, resuscitation at delivery, illness severity at admission, intratracheal ventilation and sepsis were the independent risk factors for the mortality of NRF. The length and cost of NICU stay for survivors reflected care burden in the era of universal health insurance.
CONCLUSIONS: Surfactant significantly improved the survival of neonates with NRF and RDS, reflecting the respiratory care standard in emerging regional neonatal-perinatal care network with limited resources.

Entities:  

Keywords:  Epidemiology; mortality; neonate; prematurity; respiratory distress syndrome; respiratory failure; respiratory therapy; surfactant

Mesh:

Substances:

Year:  2016        PMID: 27651118     DOI: 10.1080/14767058.2016.1238894

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  6 in total

Review 1.  [Research advances in the methods for weaning from high-frequency oscillatory ventilation in neonates].

Authors:  Ming-Yuan He; Xin-Zhu Lin
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-12

2.  [Application of two noninvasive scores in predicting the risk of respiratory failure in full-term neonates: a comparative analysis].

Authors:  Yan-Hong Zhao; Ya-Juan Liu; Xiao-Li Zhao; Wei-Chao Chen; Yi-Xian Zhou
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-04-15

3.  Outcome of very preterm infants delivered outside tertiary perinatal centers in China: a multi-center cohort study.

Authors:  Shulin Pan; Siyuan Jiang; Su Lin; Shoo K Lee; Yun Cao; Zhenlang Lin
Journal:  Transl Pediatr       Date:  2021-02

4.  Therapeutic effects and outcomes of rescue high-frequency oscillatory ventilation for premature infants with severe refractory respiratory failure.

Authors:  Jen-Fu Hsu; Mei-Chin Yang; Shih-Ming Chu; Lan-Yan Yang; Ming-Chou Chiang; Mei-Yin Lai; Hsuan-Rong Huang; Yu-Bin Pan; Ren-Huei Fu; Ming-Horng Tsai
Journal:  Sci Rep       Date:  2021-04-19       Impact factor: 4.379

5.  Discharge against medical advice among infants with 24-31 weeks' gestation admitted to Chinese neonatal intensive care units: A multicenter cohort study.

Authors:  Wenlong Xiu; Ruimiao Bai; Xinyue Gu; Siyuan Jiang; Baoquan Zhang; Ya Ding; Yanchen Wang; Ling Liu; Jianhua Sun; Yun Cao; Wenhao Zhou; Shoo K Lee; Zhankui Li; Changyi Yang
Journal:  Front Pediatr       Date:  2022-08-16       Impact factor: 3.569

6.  Outcome of neonatal hypoxemic respiratory failure: a livebirth population-based retrospective survey.

Authors:  Sufang Ding; Yaling Xu; Hui Wang; Hongni Yue; Zhaojun Pan; Bo Sun
Journal:  BMC Pediatr       Date:  2022-09-17       Impact factor: 2.567

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.